These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 34976841)

  • 1. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
    Rizzo A; Ricci AD; Di Federico A; Frega G; Palloni A; Tavolari S; Brandi G
    Front Oncol; 2021; 11():803133. PubMed ID: 34976841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
    Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
    Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):333-339. PubMed ID: 35403533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
    Rizzo A; Ricci AD
    Expert Opin Investig Drugs; 2022 Apr; 31(4):415-423. PubMed ID: 34429006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination immunotherapy for hepatocellular carcinoma.
    Rimassa L; Finn RS; Sangro B
    J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
    Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
    World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting.
    Plaz Torres MC; Lai Q; Piscaglia F; Caturelli E; Cabibbo G; Biasini E; Pelizzaro F; Marra F; Trevisani F; Giannini EG
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34361985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Dyhl-Polk A; Mikkelsen MK; Ladekarl M; Nielsen DL
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34208788
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives.
    Federico P; Petrillo A; Giordano P; Bosso D; Fabbrocini A; Ottaviano M; Rosanova M; Silvestri A; Tufo A; Cozzolino A; Daniele B
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33080958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion.
    Ogasawara S; Choo SP; Li JT; Yoo C; Wang B; Lee D; Chow PKH
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for hepatocellular carcinoma.
    Childs A; Aidoo-Micah G; Maini MK; Meyer T
    JHEP Rep; 2024 Oct; 6(10):101130. PubMed ID: 39308986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.
    Rizzo A; Ricci AD; Brandi G
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review.
    Gong H; Ong SC; Li F; Shen Y; Weng Z; Zhao K; Jiang Z; Wang M
    Health Econ Rev; 2024 Jul; 14(1):48. PubMed ID: 38967718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy Updates in Advanced Hepatocellular Carcinoma.
    Singh A; Beechinor RJ; Huynh JC; Li D; Dayyani F; Valerin JB; Hendifar A; Gong J; Cho M
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma.
    Carloni R; Sabbioni S; Rizzo A; Ricci AD; Palloni A; Petrarota C; Cusmai A; Tavolari S; Gadaleta-Caldarola G; Brandi G
    J Hepatocell Carcinoma; 2023; 10():1445-1463. PubMed ID: 37701562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
    Tovoli F; De Lorenzo S; Trevisani F
    Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33023131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
    Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
    Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma.
    Shen W; Chen Y; Lei P; Sheldon M; Sun Y; Yao F; Ma L
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.